SDH-Engine

Drug Repurposing Engine

DashboardDrug CandidatesAI HypothesesResearch FeedClinical TrialsAbout / Methods

Targeting SDH-deficient GIST, paraganglioma, pheochromocytoma, RCC

This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Drug Candidates

5 candidates mapped to SDH-deficient disease pathways

All (50)established (7)clinical trial (8)preclinical (13)theoretical (22)
Belzutifan

Welireg

established

HIF-2α inhibitor

Hif Pseudohypoxia
All SDH tumors
Evidence Score
88
FDA Approved1 trial
Bevacizumab

Avastin

established

Anti-VEGF monoclonal antibody

Vegf SignalingHif Pseudohypoxia
PPGL/PCC
Evidence Score
67
FDA Approved
Ganetespib

STA-9090

theoretical

HSP90 inhibitor (non-ansamycin resorcinol-based)

Hsp90 Hif Client ChaperoneHif Pseudohypoxia
All SDH tumors
Evidence Score
28
1 trial
Dichloroacetate (DCA)
theoretical

Pyruvate dehydrogenase kinase inhibitor

Hif PseudohypoxiaOxidative Stress Ros
All SDH tumors
Evidence Score
22
Plerixafor

AMD3100, Mozobil

theoretical

CXCR4 chemokine receptor antagonist

Hif Cxcr4 Chemokine MetastasisHif Pseudohypoxia
PPGL/PCC
Evidence Score
20
FDA Approved1 trial